{"id":"NCT02773368","sponsor":"Novo Nordisk A/S","briefTitle":"A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus","officialTitle":"A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-23","primaryCompletion":"2017-09-26","completion":"2017-10-23","firstPosted":"2016-05-16","resultsPosted":"2018-10-23","lastUpdate":"2020-08-11"},"enrollment":420,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec/liraglutide","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IDegLira","type":"EXPERIMENTAL"},{"label":"IGlar","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change in HbA1c (Glycosylated Haemoglobin)","timeFrame":"Week 0, Week 26","effectByArm":[{"arm":"IDegLira","deltaMin":8.2,"sd":0.93},{"arm":"IGlar","deltaMin":8.36,"sd":1.08}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":88,"countries":["United States","Argentina","Canada","Finland","Hungary","India","Russia","Slovakia","Slovenia","Spain","Switzerland"]},"refs":{"pmids":["30761720"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":209},"commonTop":["Viral upper respiratory tract infection","Headache","Back pain","Lipase increased","Nausea"]}}